How China's drug clinical trial institution filing works
Since 1 December 2019, a hospital in mainland China no longer needs a government accreditation certificate to run registration trials for drugs. The revised Drug Administration Law replaced accreditation with record filing: an institution that meets the conditions set by the NMPA and the National Health Commission enters its information on the national drug clinical trial institution record-filing platform operated by the Center for Food and Drug Inspection (CFDI), and the platform issues a filing number. Accreditation certificates issued before 2019 are therefore not the right test of whether a site may run a trial today; the filing record is.
What a filing record contains
Filing is not one yes/no status. Each institution files a set of specialties (for example cardiology, oncology, hepatology, pediatric respiration), and a trial may only run in a filed specialty. Institutions add specialties over time, so two hospitals of similar size can differ widely: in the sample on this page, one Wuhan teaching hospital has filed 54 drug specialties, while a specialist women's hospital in Hangzhou lists four and a newer Beijing hospital lists three.
- Filing number and date - issued by the platform when the filing is completed; the filing date shows how long a site has operated under the current system.
- Filed specialties - the scope that matters for site selection. A site with an excellent oncology department but no filed oncology specialty cannot host your oncology study until it files one.
- Phase I clinical trial ward - first-in-human, healthy-volunteer and bioequivalence studies must run in a filed Phase I specialty with its own beds, so Phase I capability is a separate filter, not something implied by hospital size.
- Medical device filing - a separate record on the same platform; a hospital's device specialties often differ from its drug specialties.
Scale and geography
The platform had about 1,000 filed institutions by May 2021, and a 2025 analysis drawing on the same platform counted 1,803 as of 9 September 2025. Activity is concentrated: NMPA's annual reports on clinical trials note that leading and participating sites are still mainly in Beijing, Shanghai, Jiangsu and Guangdong. For feasibility this means a shortlist built only from well-known tertiary hospitals in tier-1 cities will compete with every other sponsor for the same investigators, while filed sites in provincial capitals may offer faster start-up for common indications.
Using filing data in site feasibility
- Start from the indication, not the hospital. Map the indication to the filed specialty names used on the platform, then list every institution that holds that specialty in your target provinces.
- Separate Phase I from Phase II-IV. Only a minority of filed institutions have a Phase I ward; a 2025 study of one western province found just 22 Phase I units among its filed institutions.
- Check filing dates. Under the 2023 NMPA inspection measures, a newly filed institution or specialty is inspected after filing, with the first inspection focused on whether the filing conditions are really met. Recent filings carry more start-up uncertainty than long-established ones.
- Confirm ethics review arrangements. Under the 2025 30-day IND review pathway, applicants must assess the ethics review capability and compliance record of the leading institution and its principal investigator, so the lead site's ethics committee is part of feasibility, not an afterthought.
The official platform is in Chinese and shows one institution record at a time. An English, attribute-joined view (province, filing number, specialties, Phase I capability) is what most international feasibility teams end up building by hand.